1. Kaprin, A.D., Starinskiy, V.V., and Shakhzadova, A.O., Zlokachestvennye novoobrazovaniya v Rossii v 2019 godu (zabolevaemost’ i smertnost’) (Malignant Neoplasms in Russia in 2019 (Morbidity and Mortality)), Moscow: MNIOI im. P.A. Gertstena—Fil. FGBU NMIC radiologii Minzdrava Rossii, 2020.
2. Siegel, R.L., Miller, K.D., and Jemal, A., Cancer statistics. 2019, CA Cancer J. Clin., 2019, vol. 69, pp. 7–34. https://doi.org/10.3322/caac.21551
3. Ferlay, J., Colombet, M., Soerjomataram, I., et al., Cancer incidence and mortality patterns in europe: estimates for 40 countries and 25 major cancers in 2018, Eur. J. Cancer, 2018, vol. 103, pp. 356–387.
https://doi.org/10.1016/j.ejca.2018.07.005
4. Mishugin, S.V., Gritskevich, A.A., Mordovin, A.A., et al., Evaluation of effect of prolonged action Somatostatin analogue Octreotide-depo on the subsequent hormonal and cytotoxic therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), Med. Sovet, 2017, vol. 14, pp. 16–21.
5. Zarif, J.C. and Miranti, C.K., The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance, Cell Signal., 2016, vol. 28, no. 5, pp. 348–356. https://doi.org/10.1016/j.cellsig.2016.01.013